• Ruthenium Red for Calcium Signaling Workflows

  2026-08-13

  Ruthenium Red is a practical Ca2+ transport inhibitor for separating calcium-dependent effects from cytoskeletal and mechanical inputs in autophagy experiments. This workflow-focused guide connects the product’s membrane-level activity with compression-induced autophagy, mitochondrial calcium uptake inhibition, and neurogenic inflammation models while emphasizing controls and troubleshooting.

• GS-4997 in Lupus Nephritis Tubulointerstitial Injury

  2026-08-13

  The 2024 FASEB Journal study identifies ASK1 signaling as a modifiable driver of tubulointerstitial injury in lupus nephritis. In lupus-prone mice and LPS-stimulated human tubular epithelial cells, GS-4997 reduced renal inflammation, fibrosis, and injury while suppressing the downstream p38/JNK pathway, providing a mechanistic basis for further preclinical investigation.

• Dabigatran etexilate: Assay Workflow Guide

  2026-08-12

  This scenario-based guide explains how Dabigatran etexilate, SKU A8381, can support thrombin-centered coagulation studies while avoiding common confounding factors in cell viability and cytotoxicity workflows. It covers mechanism, solvent compatibility, concentration design, interpretation, and practical supplier-selection criteria.

• Amyloid Beta-Peptide (1-40): Applied Workflows

  2026-08-12

  Build more reproducible Alzheimer’s disease assays with a defined Aβ40 reagent, controlled aggregation timelines, and surface-sensitive readouts. This guide connects amyloid fibril formation studies with membrane, spectroscopy, and cell-based neurotoxicity workflows while highlighting calcium-dependent experimental variables.

• DEV VP26 and the Actin–Myosin II Network

  2026-08-11

  The 2025 reference study combines VP26 affinity proteomics with genetic and pharmacological perturbation to identify the host actin–myosin II network as a regulator of duck enteritis virus proliferation. Its strongest mechanistic evidence centers on MYH9, while actin polymerization inhibitors and myosin II inhibition provide a framework for testing cytoskeletal dependency in infection models.

• Methylprednisolone: Assays and Bone-Loss Models

  2026-08-10

  Learn how to use Methylprednisolone as a controlled inflammatory trigger in macrophage, PBMC, skin-culture, and glucocorticoid-induced osteonecrosis workflows. The guide combines practical dosing, solvent handling, bone-resorption readouts, and troubleshooting with findings from a rat femoral-head study.

• GSK621: AMPK Signaling from AML to Immunometabolism

  2026-08-09

  Explore how the AMPK agonist GSK621 can connect energy sensing, AML biology, and immunometabolic assay design. This article translates recent lysosomal AMPK findings into a rigorous framework for interpreting pathway, metabolic, and phenotype-level readouts.

• 5hmC in Rice Drought Response: Context Matters

  2026-08-08

  Yan and colleagues provide the first single-base-resolution map of 5-hydroxymethylcytosine in rice and show that its abundance, genomic distribution, and transcriptional associations change during drought and rehydration. The study positions 5hmC as a context-dependent regulatory mark and offers a framework for integrating DNA hydroxymethylation assays with transcriptomic analysis in plant stress research.

• Eicosapentaenoic Acid: Applied Research Workflows

  2026-08-07

  Eicosapentaenoic Acid (EPA) supports controlled studies of membrane remodeling, lipoprotein oxidation, and endothelial behavior. This workflow also shows how to translate an arachidonic-acid immune study into a carefully bounded EPA comparison without overstating vaccine-adjuvant evidence.

• I-BET-762: Enabling Translational Leaps in BET-Targeted Rese

  2026-08-07

  This article explores the mechanistic and translational frontiers of I-BET-762, a potent and selective BET inhibitor, in the context of ferroptosis, inflammation, and cancer biology. Bridging recent discoveries with protocol guidance, it demonstrates how I-BET-762 empowers researchers to dissect BRD4-regulated cell death and transcriptional programs, while addressing practical considerations and future outlooks for preclinical and translational impact.

• Tyrothricin: Advanced Mechanistic Insights for Antimicrobial

  2026-08-06

  Explore the peptide antibiotic mixture Tyrothricin and its unique, multi-modal antimicrobial mechanism. This article delves into underexplored mechanistic links, protocol parameters, and translational relevance, providing new depth for researchers in infection biology.

• HDAC3–NRF2–GPX4 Axis Controls Ferroptosis in Colorectal Canc

  2026-08-06

  This study identifies histone deacetylase 3 (HDAC3) as a key epigenetic suppressor of ferroptosis in colorectal cancer cells via the NRF2–GPX4 signaling pathway. The findings illuminate a critical mechanism of ferroptosis resistance and suggest new therapeutic angles for sensitizing tumors to ferroptosis-based interventions.

• GDC-0068 (RG7440): Unraveling Nuclear mTORC1 via Pan-AKT Inh

  2026-08-05

  Explore how APExBIO’s GDC-0068 (RG7440), a pan-AKT inhibitor, empowers translational researchers to interrogate spatially distinct pools of mTORC1, particularly its nuclear functions, bringing new mechanistic clarity and strategic guidance to PI3K/Akt/mTOR pathway research in tumorigenesis.

• Catalpol: Translational Leverage for Disease Modeling & Ther

  2026-08-05

  Catalpol, a natural iridoid glycoside derived from Rehmannia, is transforming translational research by targeting multiple disease pathways. This article synthesizes mechanistic evidence—including anti-inflammatory, neuroprotective, and anti-metastatic properties—while offering protocol guidance and strategic insights for translational researchers. Bridging preclinical workflows and emerging cancer data, it positions Catalpol as a keystone compound in advanced disease modeling.

• OMV-Mediated mRNA Display: A Novel Platform for Tumor Vaccin

  2026-08-04

  Li et al. introduce an innovative method using genetically engineered bacterial outer membrane vesicles (OMVs) to rapidly display and deliver mRNA antigens for personalized tumor vaccination. This approach overcomes key limitations of lipid nanoparticle-based systems, enabling faster, more immunogenic vaccine production and robust antitumor immune responses.

450 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page